A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation - 16/06/24
Abstract |
Drug resistance in hepatocellular carcinoma has posed significant obstacles to effective treatment. Recent evidence indicates that, in addition to traditional gene mutations, epigenetic recoding plays a crucial role in HCC drug resistance. Unlike irreversible gene mutations, epigenetic changes are reversible, offering a promising avenue for preventing and overcoming drug resistance in liver cancer. This review focuses on various epigenetic modifications relevant to drug resistance in HCC and their underlying mechanisms. Additionally, we introduce current clinical epigenetic drugs and clinical trials of these drugs as regulators of drug resistance in other solid tumors. Although there is no clinical study to prevent the occurrence of drug resistance in liver cancer, the development of liquid biopsy and other technologies has provided a bridge to achieve this goal.
Le texte complet de cet article est disponible en PDF.Abbreviations : HCC,, DNMT,, CpG,, TET,, 5mC,, 5hmC,, AID,, Ψ,, M1A,, M6A,, UTR,, METTL3,, FTO,, HMT,, EZH2,, HDMT,, HDAC,, HAT,, Ub,, DUB,, TRAIL,, 5-aza-CR,, EMT,, RAR,, RXR,, ATRA,, PD-L1,, PD-1,, M7G,, WDR4,, ABC,, MDR1,, CSC,, PCK,, IDH,, FDA,, CR,, HBV,, HCV,, DDR
Keywords : Liver cancer, Drug resistance, Epigenetic
Plan
Vol 176
Article 116902- juillet 2024 Retour au numéro
Article précédent
- Autophagy: A potential target for natural products in the treatment of ulcerative colitis
- Wei Zhang, Menglong Zou, Jia Fu, Yin Xu, Ying Zhu
- Recent advances in hematopoietic cell kinase in cancer progression: Mechanisms and inhibitors
- Qiting Zeng, Jun He, Xiguang Chen, Qiong Yuan, Liyang Yin, Yuxin Liang, Xuyu Zu, Yingying Shen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?